AlphAIAlphAI — Financial news for AI agents
investing.com$IMTX

Immatics NV earnings missed by €0.05, revenue fell short of estimates

Immatics NV (IMTX) reported Q3 EPS of €-0.50, missing estimates by €0.05, and revenue of €6.9M, below expectations of €10.88M. The stock is down 31.89% over 3 months and 30.58% over 12 months. InvestingPro rates its financial health as 'weak performance'.

Original reporting
investing.com
Published Nov 10, 2026, 4:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 4:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$IMTX
Bearish
high confidence
Mentioned
$IMTX
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$IMTXBearishMed
01

Why it matters

The earnings miss reinforces concerns about the company's near‑term cash burn and may prompt short‑selling activity.

02

Market read

The earnings miss provides a fresh catalyst for traders to reassess IMTX's valuation and risk.

03

What to watch

Potential upcoming clinical trial data or partnership announcements could offset the earnings disappointment.

Relevance 6/10Novelty 7/10Timing: post-market

Background

Immatics NV is a European biotech focused on cancer immunotherapies. The company has struggled with revenue growth and profitability.

Company-level read

Ticker impact

$IMTXBearishHigh confidence
Context

Immatics NV reported Q3 earnings that missed estimates on both EPS and revenue.

Expected impact

downward pressure as the market prices in the earnings miss

Evidence & confidence

Both EPS and revenue were below consensus, and the stock has already fallen sharply in recent months.

Market effects

Sector

The miss may weigh on other small-cap biotech firms with similar risk profiles.

Regional

Limited to European biotech investors; no broad regional effect.

Global

Minimal global impact given the company's size.

Counterpoint

What could challenge this read

Some investors may view the steep price decline as a buying opportunity if the miss is seen as a temporary setback.

Key entities

  • Company
    Immatics NV

    European biotech firm listed on NASDAQ under IMTX.

Read at source← All news

Related articles

$IMTXMedAI 8/10

Immatics Announces Third Quarter 2026 Financial Results and Business Update

Immatics reported Q3 2026 results, highlighting progress in its SUPRAME Phase 3 trial for anzu-cel (IMA203) in advanced melanoma, with enrollment on track to complete by year-end. Topline data is expected in H1 2027, followed by a BLA submission. The company also presented updated Phase 1 data for IMA203CD8 and IMA402 at ESMO Congress 2026, showing promising anti-tumor activity. Immatics had $536.3 million in cash as of September 30, 2026, projecting runway into Q4 2028.

finanznachrichten.de
$IMTXMed

Immatics N.V. (IMTX): Financial results for 9M 2026

Immatics N.V. (IMTX) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 PRELIMINARY NOTE The unaudited interim condensed Consolidated Financial Statements for the three- and nine-month period ended September 30, 2026, included herein, have been prepared in accordance with International Accounting Standard 34 (“Interim Financial Reporting

SEC EDGAR 6-K
$IMTXMedAI 8/10

One-time cell therapy at clinically relevant doses had a 55% confirmed response rate in 20 gynecologic cancer patients.

Immatics N.V. (IMTX) reported updated clinical trial data for IMA402 and IMA203CD8. IMA402 showed a 32% cORR and 91% 1-year OS in advanced melanoma patients. IMA203CD8 achieved a 55% cORR in gynecologic cancers with a median DOR of 8.4 months. Both treatments demonstrated favorable safety profiles. The data were presented at the ESMO 2026 meeting.

stocktitan.net